Former Verily leaders launched Tesorai, an AI platform company built to extract more signal from mass spectrometry proteomics datasets, and announced a $5.3 million seed funding round, bringing total funding to $8 million. The company says it processes raw mass spectrometry data from new experiments as well as public and archived repositories, with named collaborators including teams at MD Anderson Cancer Center, New York University, and the Michael J. Fox Foundation. Tesorai plans to expand partnerships with biopharma and research organizations and to extend its platform beyond proteomics to other molecular data types. For biotech teams, the near-term relevance is practical: proteomics workflows often bottleneck on interpretation and data integration, and new AI-enabled tooling can accelerate biomarker and target discovery cycles when data can be reliably processed and compared.